Skip to main content
. 2015 Apr 22;61(4):651–660. doi: 10.1093/cid/civ327

Figure 2.

Figure 2.

Differential effects of antiretroviral therapy on markers of inflammation and coagulation and markers of immune activation. Point estimates and error bars reflect mean and 95% confidence intervals, respectively. GlycA was not assayed at week 96. Early change represents change from baseline to week 24 (cellular markers) or week 48 (plasma markers); late change represents change from baseline to week 96 (soluble and cellular markers). Abbreviations: ATV/r, atazanavir/ritonavir; DRV/r, darunavir/ritonavir; hsCRP, high-sensitivity C-reactive protein; IL, interleukin; MNC, monocytes; RAL, raltegravir; sCD14, soluble CD14; sCD163, soluble CD163.